ArticleEuropean journal of pharmacology2008
Differential effects of triptolide and tetrandrine on activation of COX-2, NF-kappaB, and AP-1 and virus production in dengue virus-infected human lung cells.
Article in European journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan-Coronavirus Inhibitor.MedComm · 2025Article
- Insights on exploring the therapeutic potential and structural modification of Tetrandrine.Future medicinal chemistry · 2024Review
- Article
- Bis-Benzylisoquinoline Alkaloids Inhibit Porcine Epidemic Diarrhea Virus In Vitro and In Vivo.Viruses · 2022Article
- Diterpenes/Diterpenoids and Their Derivatives as Potential Bioactive Leads against Dengue Virus: A Computational and Network Pharmacology Study.Molecules (Basel, Switzerland) · 2021Article
- Small Molecule Drug Candidates for Managing the Clinical Symptoms of COVID-19: a Narrative Review.Biomolecules & therapeutics · 2021Review
- Plant Alkaloids Inhibit Membrane Fusion Mediated by Calcium and Fragments of MERS-CoV and SARS-CoV/SARS-CoV-2 Fusion Peptides.Biomedicines · 2021Article
- Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Review
- Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.Cell reports · 2021Article
- anti-HCoV: A web resource to collect natural compounds against human coronaviruses.Trends in food science & technology · 2020Review
- Alkaloids: Therapeutic Potential against Human Coronaviruses.Molecules (Basel, Switzerland) · 2020Article
- PAK1-blockers: Potential Therapeutics against COVID-19.Medicine in drug discovery · 2020Review
- A critical review: traditional uses, phytochemistry, pharmacology and toxicology ofPhytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2020Review
- Anti-inflammatory Compound Shows Therapeutic Safety and Efficacy against Flavivirus Infection.Antimicrobial agents and chemotherapy · 2019Article
- Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells.Biomolecules · 2019Article
- Epigenetic regulation of COX‑2 expression by DNA hypomethylation via NF‑κB activation in ketamine‑induced ulcerative cystitis.International journal of molecular medicine · 2019Article
- JNK/AP-1 activation contributes to tetrandrine resistance in T-cell acute lymphoblastic leukaemia.Acta pharmacologica Sinica · 2017Article
- Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents.Scientific reports · 2017Article
- Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy.Oncotarget · 2016Review
- Protective Effect of Tetrandrine on Sodium Taurocholate-Induced Severe Acute Pancreatitis.Evidence-based complementary and alternative medicine : eCAM · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most virus infections induce cycloxygenase-2 (COX-2) expression and subsequent prostaglandin E(2) (PGE(2)) production in cells, an inflammatory response that might be detrimental to virus replication and pathogenesis. This response in dengue virus infection remains to be elucidated. Triptolide and tetrandrine, compounds derived from two commonly used Chinese herbs, both demonstrate anti-inflammatory and immunosuppressive effects partly through modulation of COX-2 expression and, hence, may have antiviral effects. In this study, we examined, firstly, the immune response to dengue virus infection with respect to COX-2 expression and PGE(2) production in human lung cells (A549), liver cells (HepG2) and dendritic cells. Secondly, we assessed the potential antiviral effects of triptolide and tetrandrine on dengue virus infection vis-à-vis expression of COX-2, PGE(2), transcription factors, as well as virus production. We found that dengue virus infection enhanced COX-2 expression and PGE(2) production in A549 cells, similarly to the response in dendritic cells, but not in HepG2 cells. In dengue virus-infected A549 cells, nuclear factor kappaB (NF-kappaB) and activator protein 1 (AP-1) were also activated, and both were dose-dependently inhibited by triptolide (0.5-4 ng/ml). Tetrandrine (1-10 microM) had no similar immunosuppressive effects and, moreover, at higher concentrations, enhanced NF-kappaB and AP-1 activity, COX-2 expression and PGE(2) production. However, unexpectedly, tetrandrine, but not triptolide, dose-dependently suppressed dengue virus production in A549 cells, independent of PGE(2) level. Our findings imply that triptolide and tetrandrine may attenuate dengue virus infection in human lung cells, but through distinct pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.